Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O60292
UPID:
SI1L3_HUMAN
Alternative names:
SPA-1-like protein 3
Alternative UPACC:
O60292; Q2TV87
Background:
Signal-induced proliferation-associated 1-like protein 3, also known as SPA-1-like protein 3, plays a pivotal role in lens epithelial cell morphogenesis, polarity, adhesion, and cytoskeletal organization. This protein's involvement is crucial for maintaining the clarity and proper function of the lens, as highlighted in research findings (PubMed:26231217).
Therapeutic significance:
Cataract 45, a condition characterized by the opacification of the lens leading to visual impairment or blindness, is directly associated with variants affecting this protein. Understanding the role of Signal-induced proliferation-associated 1-like protein 3 could open doors to potential therapeutic strategies for this and possibly other related ocular diseases.